An EZH2 inhibitor, tazemetostat, is currently in multiple early phase clinical trials for both solid tumors and lymphomas, in combination with other agents including immunotherapy and chemotherapy [22] (clinicaltrials.gov). Here, EZH2 is linked to lymphoma.